Clinical trial

A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction

NCT02992288

Drugs and interventions used in this trial

6 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Neladenoson bialanate (BAY1067197) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-02-22

PhasePHASE2

Conditions

Heart Failureverified · MONDO: heart failure

Interventions

Neladenoson bialanate (BAY1067197)DRUG

PlaceboDRUG

Sponsors & collaborators

Bayerlead sponsor

Mapped research locations

SofiaBulgaria3 MadridSpain2 ValenciaSpain2 JerusalemIsrael2 HoustonTexas, United States1 St LouisMissouri, United States1 BerlinGermany1 DetroitMichigan, United States1 AmsterdamNetherlands1 KrakowPoland1 PoznanPoland1 AthensGreece1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02992288 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.